Introduction {#Sec1}
============

Human immune deficiency virus (HIV) infection remains a public health problem worldwide with about 36.9 million infections as at 2017. Sub Saharan Africa bears the greatest burden with about 25.7 million cases \[[@CR1]\]. Generally, viral hepatitis B (HBV) and C (HCV) infections are common among people living with HIV/AIDS (PLWHA) because they tend to share the same routes of transmission \[[@CR2]\]. Worldwide, about 5--20% of PLWHA are co-infected with HBV \[[@CR3]\]. In Sub-Saharan Africa, the prevalence of HIV/HBV co-infection ranges between 0 and 28.4% \[[@CR4], [@CR5]\]. Globally, the prevalence of HIV/HCV co-infection is about 6.2% with about 2.3 million people affected \[[@CR6]\].

The introduction of antiretroviral therapy (ART) for HIV treatment has led to reduced mortality among people living with HIV/AIDS (PLWHA) \[[@CR7]\]. However, non-HIV related conditions such as hepatic and renal dysfunction are increasingly recognized to contribute to morbidity and mortality in HIV patients \[[@CR8]\]. Attributive factors could be co-infection with HBV and HCV coupled with hepatotoxic/nephrotoxic impacts of ART \[[@CR8], [@CR9]\].

While the hepatological impact of HBV and HCV infections is well recognized, strong associations have been observed between these viral infections and renal disease \[[@CR10], [@CR11]\]. The pathogenesis and pathology of renal disease caused by these viruses has been extensively reviewed elsewhere \[[@CR12]\]. Increasingly, co-infections with viral hepatitis are recognized to complicate clinical profiles \[[@CR13]\], and among pregnant women, an increased disease burden has been reported \[[@CR14], [@CR15]\]. For HIV positive patients on ART, co-infection with HBV and/or HCV could exacerbate liver and kidney dysfunction. Therefore, early diagnosis of co-infected individuals and the initiation of appropriate treatment protocols are imperative. Although the World Health Organization (WHO) recommends screening of all newly diagnosed HIV individuals for HBV and HCV \[[@CR16]\], most resource-limited countries including Ghana are yet to include this in their HIV control programmes \[[@CR17]\]. Therefore, we undertook this pilot study to determine the prevalence of HBV and HCV and associated co-morbid conditions such as hepatic and renal dysfunction in newly diagnosed HIV infected patients attending the Cape Coast Teaching Hospital HIV clinic, prior to initiation of ART.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Study area, design and population {#Sec4}

The study was undertaken at Cape Coast Teaching Hospital in the Cape Coast Metropolitan area of the Central Region of Ghana. This was a hospital-based retrospective cross-sectional study undertaken from January to May 2017. Newly diagnosed HIV patients who were attending the Cape Coast Teaching Hospital HIV Clinic were recruited into the study after informed consent was sought. At the clinic, patients confirmed to have HIV were assessed clinically by physicians to determine the WHO clinical stage and their suitability for treatment. The patients then undertook liver and kidney function tests, and full blood count test. HBV and HCV testing were performed during their subsequent visit prior to initiation of ART.

### Data collection and processing {#Sec5}

Demographic data (including age, sex, marital, occupational and educational statuses) and HIV clinical stage; which is based on the WHO clinical staging of HIV \[[@CR18]\] were obtained from patients' records.

Laboratory test results were retrieved from patients' records. Full blood count data collected included hemoglobin concentration (g/dL) and platelet count (10^9^/L). Other results collected included creatinine concentration, alanine aminotransferase (ALT) concentration and aspartate aminotransferase (AST) concentration.

Hepatotoxicity was diagnosed if ALT concentrations were ≥ 50.0 U/L, and was categorized as Grades 1, 2 and 3 and 4, with ALT value of 50.0--99.9 U/L, 100.0--199.9 U/L and ≥ 200.0 U/L respectively \[[@CR19]\]. To determine whether a patient has liver fibrosis, we calculated the aspartate-platelet ratio index using the formula: APRI = (AST/ULN) × 100)/platelet count (10^9^/L) (<https://www.hepatitisc.uw.edu/page/clinical-calculators/apri>). Where ULN represents the upper limit of normal range values for AST. Normal liver function was defined by APRI \< 1.5, while liver fibrosis was defined by APRI \> 1.5.

To determine renal function of the patients, estimated glomerular filtration rate (eGFR) was obtained using the online eGFR calculator at <https://www.niddk.nih.gov/health-information/communication-programs/nkdep/laboratory-evaluation/glomerular-filtration-rate-calculators/ckd-epi-adults-conventional-unit>. Parameters including serum creatinine concentration in mg/dL, race and gender were used \[[@CR20]\]. Chronic kidney disease (CKD) stages were categorized based on the Kidney Disease Outcomes Quality Initiative classification by the National Kidney Foundation \[[@CR21]\]. For this study, CKD was defined by CKD stages 3, 4 and 5 (with eGFR 30--59 mL/min/1.73 m^2^, 15--29 mL/min/1.73 m^2^ and \< 15 mL/min/1.73 m^2^ respectively) while normal kidney function was defined by CKD stages 1 and 2 (with eGFR ≥ 90 mL/min/1.73 m^2^ and 60--89 mL/min/1.73 m^2^ respectively) \[[@CR21], [@CR22]\].

### Hepatitis B and C testing {#Sec6}

Testing for HBV infection was undertaken using the Hepatitis B combo test kit (Gemc Technology Group, Zhengzhou, Henan, China). Briefly, about 2.5 µL of capillary blood was taken from a finger prick. About 0.5 µL of the capillary blood each was spotted into wells assigned to HBsAg, HBsAb, HBeAg, HBeAb and HBcAb and a buffer solution applied immediately. HCV infection was tested using rapid anti-HCV test strip (Intec Products, Xiamen, China). For both HBV and HCV tests, the procedure, results reading and interpretations were conducted with strict adherence to the manufacturer's protocol.

### Statistical analysis {#Sec7}

Data were entered into excel and the analyses done with Graphpad Prism 6 (GraphPad Software Inc., San Diego, USA) and SPSS Version 20 (IBM Corporation, Chicago, USA). Parametric variables were presented as mean and standard deviation and compared by unpaired Student t-test. Non-parametric variables were described as median and interquartile range and compared by Mann--Whitney test. Categorical variables on the other hand were presented as proportions, with 95% confidence interval and compared by Pearson's Chi-square test or Fisher's exact test.

Results {#Sec8}
-------

### Socio-demographic characteristics of study participants {#Sec9}

The mean age ± SD of the 90 participants was 42.8 ± 8.2, and most (n = 63, 70.0%) were aged between 36 and 55 years (Table [1](#Tab1){ref-type="table"}). Majority of the participants were married (n = 76, 84.4%), and most of them were females (n = 58, 64.4%) (Table [1](#Tab1){ref-type="table"}). Although 92.2% (n = 83) of the participants had lower forms of education (none or basic form of formal education), about 94.6% (n = 85) had some form of employment (Table [1](#Tab1){ref-type="table"}).Table 1Distribution of socio-demographic characteristics among the study participants (n = 90)CategorySub-categoryn (%)95% CIAge18--3520 (22.2)26.3, 31.436--5563 (70.0)43.8, 46.556+7 (7.8)55.5, 65.6SexFemale58 (64.4)53.9, 73.8Male32 (35.6)26.2, 46.1Marital StatusMarried76 (84.4)75.2, 90.7Widowed2 (2.2)0.5, 8.7Single10 (11.1)6.0, 19.6Divorced1 (1.1)0.2, 7.7Cohabiting1 (1.1)0.2, 7.7Occupational statusEmployed85 (94.6)88.6, 98.4Student/unemployed5 (4.4)1.6, 11.4Highest educational levelNone50 (55.6)45.0, 65.6Basic33 (36.7)27.2, 47.3Secondary6 (6.7)3.0, 14.2Tertiary1 (1.1)0.2, 7.7Socio-economic determinants were presented as numbers and proportions \[n (%)\], with 95% confidence intervals (95% CI). None and basic: lower forms of education, secondary and tertiary: higher forms of education

### Prevalence of viral hepatitis B or C in newly diagnosed HIV infections {#Sec10}

All the 90 participants tested positive for HIV1 with none testing positive for HIV2. Among the participants, 24.4% (n = 22) tested positive for both HBsAg and HBcAb, 5.6% (n = 5) tested positive for HBsAb, 2.2% (n = 2) tested positive for HBeAg and 8.9% (n = 8) tested positive for HBeAb. The prevalence of HIV1 mono-infection was 75.6% (n = 68) and that of HIV1/HBV co-infection was 24.4% (n = 22). We did not record any HCV infection.

### Diagnosis of HIV clinical stages {#Sec11}

Majority of the participants, 71.1% (n = 64, 95% CI 60.7--79.7), were diagnosed with HIV stage 1. Of the remaining participants, 14.4% (n = 13, 95% CI 8.5--23.5) had HIV stage 2, 7.8% (n = 7, 95% CI 3.7--15.6) had HIV stage 3 and 6.7% (n = 6, 95% CI 3.0--14.2) had HIV stage 4.

### Comparison of socio-economic variables between the different groups of HIV infections {#Sec12}

The mean age between the HIV1 mono-infection and HIV1/HBV co-infection groups was similar (*p *= 0.984, Table [2](#Tab2){ref-type="table"}). Also, infection with either HIV1 or HIV1/HBV was independent of age group (*p *= 0.808), gender (*p *= 0.927), marital status (*p *= 0.819), level of education (*p *= 0.480) and occupational status (*p *= 0.569) (Table [2](#Tab2){ref-type="table"}).Table 2Association between socio-demographic factors and HIV infection typeCharacteristicsHIV1 mono-infection\
(n = 68)HIV1/HBV co-infection\
(n = 22)*p*-valueAge, mean ± SD42.9 ± 10.442.8 ± 8.20.984Age group, n (%) 18--3515 (16.7)5 (5.6)0.808 36--5547 (52.2)16 (17.8) 56+6 (6.7)1 (1.1)Sex, n (%) Female44 (48.9)14 (15.6)0.927 Male24 (26.7)8 (8.9)Marital status, n (%) Married56 (62.2)20 (22.2)0.819 Widowed2 (2.2)0 (0.0) Single8 (8.9)2 (2.2) Divorced1 (1.1)0 (0.0) Cohabiting1 (1.1)0 (0.0)Occupational status, n (%) Employed64 (71.2)22 (24.4)0.569 Student/unemployed4 (4.4)0 (0.0)Highest educational level, n (%) None24 (26.7)9 (10.0)0.480 Basic37 (41.1)13 (14.4) Secondary6 (6.7)0 0.0) Tertiary1 (1.1)0 (0.0)Unpaired t-test was used to compare the exact ages between the mono-infected and co-infected participants. Where SD = standard deviation of the mean ages. Association analyses between infection type and the socio-economic determinants were done using Pearson's Chi-square test or Fisher's exact test. A two-tailed *p*-value was considered significant at *p *\< 0.05

### Prevalence of hepatic damage, liver fibrosis and CKD among the newly diagnosed HIV infections {#Sec13}

The levels of hematological indices \[Hb (*p* = 0.917) and PLT (*p* = 0.460)\], liver chemistry \[ALT (*p* = 0.821) and AST (*p* = 0.123)\] and renal chemistry \[creatinine (*p* = 0.351)\] tests were observed to be similar in both HIV1 and HIV1/HBV groups (Table [3](#Tab3){ref-type="table"}). The prevalence of hepatotoxicity, liver fibrosis, and chronic kidney disease (CKD) were 7.8% (n = 7), 2.2% (n = 2), and 15.5% (n = 14) respectively. Similar proportions of the HIV1 and HIV1/HBV groups were diagnosed with hepatotoxicity (*p* = 0.355), liver fibrosis (*p *= 0.431) and CKD (*p* = 0.696) (Table [3](#Tab3){ref-type="table"}). In relation to the hepatotoxicity Grade, a high proportion of those with HIV1/HBV were diagnosed with Grade 2 (*p *= 0.042, Table [3](#Tab3){ref-type="table"}). Also, severely reduced kidney function (CKD stage 4) was recorded in only those with HIV1/HBV (n = 2, 9.1%), and such an observation was nearly significant (*p* = 0.053, Table [3](#Tab3){ref-type="table"}). That notwithstanding, no differences in HIV clinical stages were observed between the two groups (*p* = 0.86, Table [3](#Tab3){ref-type="table"}).Table 3Association between HIV clinical data and HIV infection typeClinical dataDescriptionHIV1 mono-infection\
(n = 68)HIV1/HBV co-infection\
(n = 22)*p*-valueMedian (IQR)Hb (g/dL)10. 0 (8.5--11.8)10.4 (8.8--11.4)0.917PLT (10^9^/L)208 (165.0--245.0)230 (167.3--256.3)0.460ALT (U/L)28.1(18.1--34.7)25.6 (17.3--45.3)0.821AST (U/L)30.6 (23.8--45.0)33.0 (27.5--58.9)0.123Creatinine (mg/dL)80.0 (65.1--106.2)89.8 (62.0--118.2)0.351ALT (U/L)Hepatotoxicity, n (%)Absent\< 50.064 (91.4)19 (86.4)0.355Present≥ 50.04 (5.9)3 (13.6)Grade 150.0--99.94 (5.9)1 (4.5)0.042Grade 2100.0--199.90 (0.0)2 (9.1)Grade 3 and 4≥ 200.00 (0.0)0 (0.0)APRILiver fibrosis, n (%)Absent\< 1.567 (98.5)21 (95.5)0.431Present\> 1.51 (1.5)1 (4.5)eGFR (mL/min/1.73 m^2^)CKD, n (%)Absent≥ 6058 (85.3)18 (81.8)0.696Present\< 6010 (14.7)4 (18.2)Stage 1≥ 90Normal GFR40 (58.8)10 (45.5)0.053Stage 260--89Mildly reduced GFR18(26.5)8 (36.4)Stage 330--59Moderately reduced GFR10 (14.7)2 (9.1)Stage 415--29Severely reduced GFR0 (0.0)2 (9.1)n (%)HIV stagesStage 147 (52.2)17 (18.9)0.86Stage 210 (11.1)3 (3.3)Stage 36 (6.7)1 (1.1)Stage 45 (5.6)1 (1.1)Mann--Whitney test was used to compare levels of Hb, PLT, ALT and AST. Where IQR = interquartile range. Association analyses of infection type with hepatotoxicity, liver fibrosis CKD or HIV stages were done using Pearson's Chi-square test or Fisher's exact test. A two-tailed *p*-value was considered significant at *p *\< 0.05

Discussion {#Sec14}
----------

HIV infection complicated by HBV and HCV infection increases the risk of morbidity and mortality compared with HIV mono-infection. Because treatment increases the survival of co-infected individuals compared with the untreated, it is recommended to routinely check for HBV and HCV status of all newly diagnosed patients. However, in most resource-limited countries including Ghana, this recommendation is yet to be included in HIV control programmes. In this pilot study, all newly diagnosed patients were HIV1 positive with none testing positive for HIV2 infection. In Ghana, 98.5% of HIV infections are due to the type 1 mono-infection, with the rest being dual type 1 and 2 infections \[[@CR23]\]. The 22.4% prevalence of HIV/HBV co-infection falls within the range of 0 to 28.4% reported in sub Saharan Africa \[[@CR7]\]. This prevalence was as expected, as most HBV acquisition in Sub-Sahara Africa, including Ghana, is before age 6 years, thus, HIV/HBV co-infection usually mirrors the national HBV prevalence \[[@CR5], [@CR24]\]. We did not record any case of HIV/HCV co-infection, probably because, the prevalence of this co-infection tends to be lower in sub Saharan Africa; where intravenous drug injection is less prevalent \[[@CR6]\]. However, Ntiamoah in 2015 reported an HIV/HCV prevalence in Ghanaian pregnant women as 4.1% \[[@CR25]\] whereas Brandful et al. reported a prevalence of 8.2% among patients attending sexually transmitted disease clinics in 1999 \[[@CR26]\].

To determine the impact of HIV/HBV co-infection on liver morbidity such as hepatotoxicity and liver fibrosis in our study participants, we utilized surrogates such ALT, AST, APRI and degree of hepatotoxicity. We observed no significant differences in these surrogates, that notwithstanding, studies in Tanzania reported a significantly higher AST and ALT concentration in HIV/HBV co-infected individuals compared with HIV mono-infected \[[@CR27], [@CR28]\]. Though several non-invasive measurements exist for diagnosing liver fibrosis \[[@CR29], [@CR30]\], the APRI is recommended by the WHO for assessing the presence of liver fibrosis in the absence liver biopsy \[[@CR17], [@CR31]\]. Using \> 1.5% APRI proxy, the study reports a prevalence of 2.2% of liver fibrosis among the participants, which is lower compared with high levels of liver fibrosis reported elsewhere in Sub Saharan Africa \[[@CR27], [@CR32], [@CR33]\]. Even though HIV/HBV co-infected patients are at an increased risk of developing liver fibrosis compared with HIV mono-infected individual \[[@CR34]\], our findings revealed that co-infection was independent of liver fibrosis. The prevalence of hepatotoxicity was 7.8%, which compares with the 6.5% reported in Ethiopia \[[@CR35]\], however, the higher rate in this study could be due to the presence of co-infection with HBV.

The use of tenofovir and/or lamivudine in ART combination for treating HIV complicated with HBV co-infection has been recommended irrespective of the immune state of the patients \[[@CR36]\]. However, these drugs have been found to increase the risk of developing nephrotoxicity in these patients \[[@CR35], [@CR37], [@CR38]\]. Therefore, assessment of the renal function prior to treatment has been recommended \[[@CR16], [@CR37]\]. The 15.5% prevalence of CKD in the newly diagnosed compares with a high rate of 22.9% recorded in Nigeria \[[@CR39]\]. kidney failure may result from HIV-associated nephropathy, which is common in the Africans with contributory factors such as co-infection with HBV or HCV \[[@CR40], [@CR41]\]. Therefore, our finding of higher proportions of HIV1/HBV co-infected individuals with severe forms of CKD (CKD 4) buttresses such findings.

Conclusion {#Sec15}
----------

In summary, the study observed that, prior to initiation of ART, severe forms of hepatotoxicity (hepatotoxicity Grade 2) and CKD (CKD stage 4) were common among HIV1/HBV co-infections. The findings buttress the need for resource-limited countries to routinely screen for hepatitis B at HIV clinics, so as to initiate appropriate treatment protocols.

Limitation {#Sec16}
==========

The sample size for the study was small, thus, future studies with a larger sample size is recommended to substantiate our findings. The underlying aetiology of liver and kidney dysfunction was unknown for the participants. Also, the study could not diagnose CKD in participants with eGFR values \> 60, since urine albumin, an alternative mean value for determining CKD was not measured.
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